tiprankstipranks
Advertisement
Advertisement

Amneal Pharmaceuticals backs FY26 adjusted EPS view 95c-$1.05, consensus $1.00

Backs FY26 revenue view $3.05B-$3.15B, consensus $3.1B. Backs FY26 adjusted EBITDA view $740M-$770M. Backs FY26 capital expenditures view $110M.

Meet Samuel – Your Personal Investing Prophet

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1